The frequencies of the various categories of adverse effects in this study were generally similar between the treatment and placebo groups.957 Furthermore, monotherapy of a selective TGF-β1/3 trap known as AVID200 in a population of patients with an advanced stage of myelofibrosis in a phase 1b trial resulted in limited toxicity as well as improvements in spleen size, symptom benefit, and platelet counts (NCT03895112). Here, TGFB1 is linked to myelofibrosis.